{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:49:10Z","timestamp":1762004950931,"version":"3.44.0"},"reference-count":23,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2018,1,3]]},"abstract":"<jats:p>Pembrolizumab is an immune checkpoint inhibitor that significantly improves clinical outcomes in numerous solid organ malignancies. Despite successful therapeutic responses, this new drug comes with a constellation of adverse reactions. Herein, we chronicle the case of a patient with metastatic non-small-cell lung cancer treated with pembrolizumab. After two cycles, he developed new-onset dyspnoea on exertion. Electrocardiogram showed idioventricular rhythm with diffuse ST-segment elevations. Echocardiography revealed severe biventricular cardiac dysfunction. Based on diagnostic workup and exclusion of probable aetiologies, the patient was diagnosed with pembrolizumab-induced myocarditis. The treatment was initiated with corticosteroids and guideline-conform heart failure therapy. He demonstrated a marked clinical response with resolution of congestive heart failure symptoms. This article summarises the clinical evidence regarding the epidemiology, pathophysiology, clinical features, diagnostic modalities and management of patients with pembrolizumab-associated myocarditis. In addition, it highlights that programmed death receptor-1 inhibition can cause a spectrum of autoimmune adverse events requiring clinical monitoring and periodic screenings.<\/jats:p>","DOI":"10.1136\/bcr-2017-223252","type":"journal-article","created":{"date-parts":[[2018,1,23]],"date-time":"2018-01-23T23:30:25Z","timestamp":1516750225000},"page":"bcr-2017-223252","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["New drugs and new toxicities: pembrolizumab-induced myocarditis"],"prefix":"10.1136","volume":"2018","author":[{"given":"Faisal","family":"Inayat","sequence":"first","affiliation":[{"name":"Allama Iqbal Medical College, Lahore, Pakistan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Masab","sequence":"additional","affiliation":[{"name":"Einstein Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sorab","family":"Gupta","sequence":"additional","affiliation":[{"name":"Einstein Medical Center, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Waqas","family":"Ullah","sequence":"additional","affiliation":[{"name":"University of Arizona, Tucson, Arizona, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,1,23]]},"reference":[{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40425-015-0078-9","article-title":"Pembrolizumab","volume":"3","author":"Khoja","year":"2015","journal-title":"J Immunother Cancer"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","author":"Davies","year":"2017","journal-title":"Immunotargets Ther"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60958-2"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.5","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2217\/imt-2017-0042","article-title":"Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma","volume":"9","author":"Smith-Cohn","year":"2017","journal-title":"Immunotherapy"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.6","doi-asserted-by":"crossref","unstructured":"Atwal D , Joshi KP , Ravilla R , et al . Pembrolizumab-induced pancytopenia: a case report. Perm J 2017;21.doi:10.7812\/TPP\/17-004","DOI":"10.7812\/TPP\/17-004"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.7","doi-asserted-by":"crossref","unstructured":"Issa M , Milioglou I . Unusual case of immune-related colitis. BMJ Case Rep 2017; 2017:bcr-2017-221319.doi:10.1136\/bcr-2017-221319","DOI":"10.1136\/bcr-2017-221319"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1001\/jamadermatol.2017.0989","article-title":"Eruptive keratoacanthomas associated with pembrolizumab therapy","volume":"153","author":"Freites-Martinez","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.9","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.mayocp.2017.03.016","article-title":"Scleroderma induced by pembrolizumab: a case series","volume":"92","author":"Barbosa","year":"2017","journal-title":"Mayo Clin Proc"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.10","doi-asserted-by":"crossref","unstructured":"March KL , Samarin MJ , Sodhi A , et al . Pembrolizumab-induced myasthenia gravis: a fatal case report. J Oncol Pharm Pract 2017:107815521668738.doi:10.1177\/1078155216687389","DOI":"10.1177\/1078155216687389"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.11","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1002\/phar.1839","article-title":"A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma","volume":"36","author":"Hanna","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-015-0057-1"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.14","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.15","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxq026"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.16","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1200389"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(11)60648-X","article-title":"Myocarditis","volume":"379","author":"Sagar","year":"2012","journal-title":"The Lancet"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.09.074"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn296"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.20","first-page":"e1326","article-title":"From the gut to the heart: campylobacter jejuni enteritis leading to myopericarditis","volume":"9","author":"Inayat","year":"2017","journal-title":"Cureus"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.21","doi-asserted-by":"crossref","unstructured":"Liao X , Li B , Cheng Z . Extracorporeal membrane oxygenation in adult patients with acute fulminant myocarditis: clinical outcomes and risk factor analysis. Herz 2017. doi: 10.1007\/s00059-017-4617-7.[Epub ahead of print 12 Sep 2017].","DOI":"10.1007\/s00059-017-4617-7"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.22","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12872-017-0686-z","article-title":"Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials","volume":"17","author":"Tai","year":"2017","journal-title":"BMC Cardiovasc Disord"},{"key":"2025082623123913000_2018.jan23_1.bcr-2017-223252.23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/bjc.2017.253","article-title":"Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy","volume":"117","author":"Tay","year":"2017","journal-title":"Br J Cancer"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2017-223252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:12:50Z","timestamp":1756275170000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2017-223252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,23]]},"references-count":23,"alternative-id":["10.1136\/bcr-2017-223252"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2017-223252","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2018,1,23]]}}}